Loading
Advanced Urothelial Carcinoma

Advanced Urothelial Carcinoma

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.

Cecilia Brown

Advanced Urothelial Carcinoma | September 22, 2022

Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.

Leah Lawrence

ESMO 2022 | September 16, 2022

The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.

Patrick Daly

Advanced Urothelial Carcinoma | March 21, 2022

Gemcitabine chemotherapy is effective at lowering the risk of recurrence in NMIBC, but development of resistance can occur.

Patrick Daly

Advanced Urothelial Carcinoma | March 9, 2022

Three biomarkers were ultimately chosen to construct the P3 panel: PCDH17, POU4F2, and PENK.

Patrick Daly

Advanced Urothelial Carcinoma | March 9, 2022

A meta-analysis evaluated the safety of laparoscopic radical cystectomy surgical therapy in patients with bladder cancer.

Patrick Daly

Advanced Urothelial Carcinoma | March 9, 2022

Alternative splicing events in patients with BLCA suggests a potential role of AS events in prognosis and immunotherapy.

Patrick Daly

Advanced Urothelial Carcinoma | March 9, 2022

MMC administration within one day of surgery can reduce the risk of recurrence after removal of a bladder tumor for NMIBC.

Patrick Daly

Advanced Urothelial Carcinoma | February 23, 2022

The variables used to develop the prognostic nomogram included summary stage, tumor size, chemotherapy, and nodes examined.

Patrick Daly

Advanced Urothelial Carcinoma | February 23, 2022

PLSWT7-DMI has been reported to be a safe approach for the improved detection of bladder cancer and thorough resection.

Patrick Daly

Advanced Urothelial Carcinoma | February 23, 2022

CTCs and CECs “may putatively guide in diagnosis, prognosis prediction, and therapeutic decision-making for bladder ...

Patrick Daly

Advanced Urothelial Carcinoma | February 23, 2022

Laparoscopic surgeries that included holmium laser-guided mucosal incisions down to the perivesical fat were analyzed.